LSM2 is an RNA-binding protein that functions in two distinct cellular compartments through association with different heptameric Lsm complexes. In the nucleus, LSM2 is a component of the U4/U6-U5 tri-snRNP complex and precatalytic spliceosome (B complex), where it binds the 3'-terminal U-tract of U6 snRNA to facilitate pre-mRNA splicing 1. The nuclear Pat1b/Lsm2-8 complex also regulates alternative splicing by modulating exon inclusion patterns 2. In the cytoplasm, LSM2 participates in mRNA decay pathways through the Lsm1-7-Pat1 complex and P-body functions 3. Clinically, LSM2 dysregulation is associated with multiple malignancies. Elevated LSM2 expression correlates with poor prognosis and aggressive phenotypes in hepatocellular carcinoma, skin cutaneous melanoma, and is a novel susceptibility gene for Hodgkin lymphoma 456. In non-malignant disease, LSM2 is critical for club cell proliferation in the lung; its inhibition exacerbates cigarette smoke-induced injury and accelerates COPD progression 7. LSM2 has been implicated in immune function as an MHC Class III-encoded RNA-binding protein associated with autoimmune diseases 8. These findings position LSM2 as a multifunctional regulator of RNA metabolism with significant therapeutic potential across diverse pathologies.